Clinical significance of serum CYFRA 21-1 in gastric cancer
1996

Clinical Significance of Serum CYFRA 21-1 in Gastric Cancer

Sample size: 110 publication Evidence: moderate

Author Information

Author(s): B Nakata, YS Chung, Y Kato, M Ogawa, Y Ogawa, A Inui, K Maeda, T Sawada, M Sowa

Primary Institution: Osaka City University Medical School

Hypothesis

What is the clinical significance of serum CYFRA 21-1 levels in patients with gastric cancer?

Conclusion

CYFRA 21-1 is a reliable tumor marker for gastric cancer that can predict advanced cases, recurrence, and overall poor prognosis.

Supporting Evidence

  • CYFRA 21-1 levels were significantly higher in patients with peritoneal and liver metastases.
  • 55.6% of stage IV cases tested positive for CYFRA 21-1.
  • Patients with CYFRA 21-1 levels above 5 ng/ml had a significantly poorer prognosis.
  • The false-positive rate in benign gastrointestinal disorders was only 2.6%.
  • Multivariate analysis indicated that CYFRA 21-1 was an independent prognostic factor.

Takeaway

Doctors can use a blood test for CYFRA 21-1 to help find out how serious someone's stomach cancer is and if it might come back.

Methodology

Sera from 110 gastric cancer patients were analyzed for CYFRA 21-1 levels using a two-step sandwich enzyme immunoassay.

Limitations

The study did not find significant differences in CYFRA 21-1 levels based on histotype, depth of invasion, or vessel invasion.

Participant Demographics

The study included 101 primary and 9 recurrent gastric cancer cases.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication